Clinical trials: Hydroxychloroquine
Kidney Failure, Chronic, Cardiovascular Disease
Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study
Presence of multiple traditional and nontraditional risk factors of atherosclerosis and cardiovascular disease (CVD) including inflammation in patients with chronic kidney disease (CKD) contribute to high CVD morbidity and…
- Conditions
- Kidney Failure, Chronic, Cardiovascular Disease, Arteriosclerosis
- Trial name
- NCT01537315
- Testing
- Hydroxychloroquine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Arkansas
COVID-19
Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers
In order to assess the efficacy of hydroxychloroquine treatment weekly for a total of 7 weeks in the prevention of COVID-19 infection, three hundred sixty (360) Healthcare workers with high risk exposure to patients infected with…
- Trial name
- NCT04333225
- Testing
- Hydroxychloroquine
- Where
- United States
- Volunteers
- 221 people, healthy volunteers welcome
- Sponsor
- Baylor Research Institute
SARS-CoV Infection, COVID 19
The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients
The (World Health Organization) WHO NOR- (Coronavirus infectious disease) COVID 19 study is a multi-centre, adaptive, randomized, open clinical trial to evaluate the safety and efficacy of hydroxychloroquine, remdesivir and…
- Conditions
- SARS-CoV Infection, COVID 19, Acute Respiratory Distress Syndrome ARDS
- Trial name
- NCT04321616
- Testing
- Hydroxychloroquine, Remdesivir, (Standard of Care) SoC
- Where
- Norway
- Volunteers
- 700 people
- Sponsor
- Oslo University Hospital
Age Related Macular Degeneration
Plaqenil Role in Prevention of Age Related Macular Degeneration
The investigators think that there is a connection between the use of plaquenil and the prevention of Age related macular degeneration (AMD).
- Trial name
- NCT01541449
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Ziv Hospital
Rheumatoid Arthritis
Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
The condition that will be studied is Rheumatoid Arthritis (RA), and in particular, RA patients with moderate to highly active disease who were prescribed Abatacept (Orencia®) (ABA) by their physician during their setting of care…
- Trial name
- NCT05782335
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Hospital for Special Surgery, New York
COVID-19, Coronavirus
Will Hydroxychloroquine Impede or Prevent COVID-19
This is a prospective, multi-site study designed to evaluate whether the use of hydroxychloroquine in healthcare workers (HCW), Nursing Home Workers (NHW), first responders (FR), and Detroit Department of Transportation bus…
- Conditions
- COVID-19, Coronavirus, Coronavirus Infections, SARS-CoV 2
- Trial name
- WHIP COVID-19 (NCT04341441)
- Testing
- Hydroxychloroquine - Daily Dosing, Hydroxychloroquine - Weekly Dosing, Monitoring Visit - Baseline
- Where
- United States
- Volunteers
- 624 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
COVID-19, Corona Virus Infection
Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)
This is a clinical study for the prevention of SARS-CoV-2 infection in adults exposed to the virus. This study will enroll up to 2000 asymptomatic men and women 18 to 80 years of age (inclusive) who are close contacts of persons…
- Conditions
- COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
- Trial name
- NCT04328961
- Testing
- Hydroxychloroquine Sulfate, Ascorbic Acid
- Where
- 8 sites in United States
- Volunteers
- 943 people, healthy volunteers welcome
- Sponsor
- University of Washington
Rheumatoid Arthritis
Open-Label Study Comparing Etanercept to Conventional Disease Modifying Antirheumatic Drug (DMARD) Therapy
The purpose of this 2 phased, open-label study is to compare the safety and efficacy of etanercept with conventional Disease Modifying Antirheumatic Drug (DMARD) therapy in Latin American subjects with moderate to severe…
- Trial name
- NCT00848354
- Testing
- Phase 1: Etanercept, Phase 1: Methotrexate, Phase 2: Optional ETN, SSZ, HCQ, MTX
- Where
- 33 sites in Argentina, Chile and 3 more
- Volunteers
- 429 people
- Sponsor
- Pfizer
Virus Diseases, Infection Viral
Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19
This study explores whether patients acutely hospitalized may have shorter hospitalization and fewer admittances at Intensive Care Units by treatment with azithromycin and hydroxychloroquine.
- Conditions
- Virus Diseases, Infection Viral, Corona Virus Infection
- Trial name
- ProPAC-COVID (NCT04322396)
- Testing
- Azithromycin, Hydroxychloroquine
- Where
- 8 sites in Denmark
- Volunteers
- 117 people
- Sponsor
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark
COVID-19
COVID-19 PrEP HCW HCQ Study
Off label study to evaluate the efficacy of HCQ for pre-exposure prophylaxis (PrEP) to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
- Trial name
- NCT04354870
- Testing
- Hydroxychloroquine (HCQ)
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- NYU Langone Health
Chronic Kidney Disease, Cardiovascular Disease
Management of Cardiovascular Disease in Kidney Disease (MaCK) Study
Cardiovascular disease (CVD) is the largest concerns for patients with Chronic kidney disease (CKD). At present time the investigators do not have proven effective strategies to reduce high CVD related deaths in CKD.
- Conditions
- Chronic Kidney Disease, Cardiovascular Disease, Inflammation, Atherosclerosis
- Trial name
- MaCK (NCT03636152)
- Testing
- MRI carotid, APWV, Hydroxychloroquine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- VA Office of Research and Development
Coronavirus Infections, Pneumonia, Viral
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II)
The Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized infectious disease of the respiratory tract.
- Trial name
- NCT04321278
- Testing
- Hydroxychloroquine + azithromycin, Hydroxychloroquine
- Where
- 58 sites in Brazil
- Volunteers
- 440 people
- Sponsor
- Hospital Israelita Albert Einstein
Antiphospholipid Syndrome in Pregnancy, Anticoagulants
HYDROxychloroquine in Syndrome Primary AntiPhospholipid
Antiphospholipid syndrome (APS) is defined by thrombosis or obstetric complication (≥ 3 spontaneous miscarriages or fetal death or prematurity <34 weeks gestation-related amenorrhea (SA)) associated with antiphospholipid…
- Trial name
- HYDROSAPL (NCT04275778)
- Testing
- Plaquenil 200Mg Tablet
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Covid19
Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment
This study is a randomized, double-blinded, and placebo controlled phase III clinical trial which aims to investigate the superiority of hydroxychloroquine, favipiravir or hydroxychloroquine + favipiravir treatment, initiated…
- Trial name
- NCT04981379
- Testing
- Hydroxychloroquine, Favipiravir, Favipiravir + Hydroxychloroquine
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 1,120 people
- Sponsor
- Health Institutes of Turkey
Pancreatic Cancer
Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in Stage IIb or III Adenocarcinoma of the Pancreas
The primary goal of the research study is to determine whether treating pancreatic cancer patients with hydroxychloroquine in combination with gemcitabine before surgery is safe.
- Trial name
- NCT01128296
- Testing
- Hydroxychloroquine, Gemcitabine
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Amer Zureikat
Covid19
The (HD)IVACOV Trial (The High-Dose IVermectin Against COVID-19 Trial)
Ivermectin, a classical antiparasitic and anti-scabies agent, has demonstrated antiviral activity for a variety of viruses including chikungunya virus, zyka virus and dengue virus and was tested as a potentially effective for…
- Trial name
- NCT04712279
- Testing
- Ivermectin 0.6mg/kg/day, Ivermectin 1.0mg/kg/day, Hydroxychloroquine
- Volunteers
- 294 people, healthy volunteers welcome
- Sponsor
- Corpometria Institute
Coronavirus Infection, Pneumonia, Viral
Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial)
Double blinded randomized clinical trial designed to evaluate the efficacy and safety of hydroxychloroquine combined with azithromycin compared to hydroxychloroquine monotherapy in patients hospitalized with confirmed COVID-19…
- Trial name
- COVIDOC (NCT04345861)
- Testing
- hydroxychloroquine + azithromycin
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University Hospital, Montpellier
Small Cell Lung Cancer
STUDY 15 - Comparing Gemcitabine/Carboplatin and Hydroxychloroquine Versus Carboplatin/Etoposide Therapy Alone in Small Cell Lung Cancer (SCLC)
To determine whether the combination of gemcitabine/carboplatin with hydroxychloroquine (HCQ) is associated with an improved clinical outcome (progression free and overall survival) compared with chemotherapy alone in patients…
- Trial name
- NCT02722369
- Testing
- Gemcitabine, Carboplatin, Etoposide
- Where
- 13 sites in United Kingdom
- Volunteers
- 72 people
- Sponsor
- University College, London
Lupus or SLE, Interstitial Lung Disease
Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease
Recent data indicate that Telitacicept is beneficial for lupus nephritis. Our goal is to determine whether Telitacicept is an effective and safe treatment, compared to standard-of-care Cyclophosphamide, for subclinical and…
- Conditions
- Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus
- Trial name
- NCT07077486
- Testing
- Methylprednisolone (Corticosteroid), Immunosuppressant other than CYC, Telitacicept Freeze-dried powder Injection 80mg
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Tongji Hospital
COVID-19
Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death
This is a multi-center, randomized controlled, superiority, open label trial. The objective of this trial is to evaluate the efficacy of HCQ in patients with newly diagnosed COVID-19 who have mild to moderate disease or at risk…
- Trial name
- NCT04323631
- Testing
- Hydroxychloroquine, The control group will not receive hydroxychloroquine
- Sponsor
- Rambam Health Care Campus